Novel strategy to restore the activity of taxanes: A multicenter phase II study of combination therapy with taxanes and toremifene at 120 mg for advanced/recurrent breast cancer—Kinki Multidisciplinary Breast Oncology Group (KMBOG0612).

Takahiro Nakayama,Takashi Arai,Jun Yamamura,Takashi Morimoto,Yoshifumi Komoike,Katsuhide Yoshidome,Shunji Kamigaki,Nobuki Matsunami,Norikazu Masuda

Novel strategy to restore the activity of taxanes: A multicenter phase II study of combination therapy with taxanes and toremifene at 120 mg for advanced/recurrent breast cancer—Kinki Multidisciplinary Breast Oncology Group (KMBOG0612).

2011

Takahiro Nakayama
Takashi Arai
Jun Yamamura
Takashi Morimoto
Yoshifumi Komoike
Katsuhide Yoshidome
Shunji Kamigaki
Nobuki Matsunami
Norikazu Masuda

e13611 Background: A preclinical study reported that toremifene (TOR) increased the level of an anticancer agent such as doxorubicin and paclitaxel in the breast cancer cell which has acquired resi...

Keywords:

Toremifene
Recurrent breast cancer
Multidisciplinary approach
Phases of clinical research
Oncology
Combination therapy
Medicine
Internal medicine
Doxorubicin
Paclitaxel
breast cancer cells

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations